Sean Nolan Sells 41,312 Shares of Taysha Gene Therapies (NASDAQ:TSHA) Stock

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) CEO Sean Nolan sold 41,312 shares of Taysha Gene Therapies stock in a transaction that occurred on Monday, January 26th. The stock was sold at an average price of $4.61, for a total transaction of $190,448.32. Following the completion of the transaction, the chief executive officer owned 2,908,257 shares of the company’s stock, valued at $13,407,064.77. This represents a 1.40% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Taysha Gene Therapies Trading Down 5.9%

Shares of NASDAQ:TSHA opened at $4.48 on Thursday. Taysha Gene Therapies, Inc. has a 52 week low of $1.05 and a 52 week high of $6.02. The company’s 50 day moving average is $5.10 and its two-hundred day moving average is $4.09. The company has a market cap of $1.23 billion, a PE ratio of -13.58 and a beta of 1.02. The company has a current ratio of 10.48, a quick ratio of 10.48 and a debt-to-equity ratio of 0.23.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its earnings results on Tuesday, November 4th. The company reported ($0.09) EPS for the quarter, hitting analysts’ consensus estimates of ($0.09). Taysha Gene Therapies had a negative net margin of 1,144.97% and a negative return on equity of 67.26%. Equities analysts predict that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on TSHA. Wells Fargo & Company upped their target price on shares of Taysha Gene Therapies from $8.00 to $11.00 and gave the company an “overweight” rating in a report on Monday, January 5th. Raymond James Financial restated a “strong-buy” rating and issued a $13.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday, January 6th. The Goldman Sachs Group set a $11.00 target price on Taysha Gene Therapies in a research report on Thursday, December 4th. Citizens Jmp upped their target price on Taysha Gene Therapies from $6.00 to $8.00 and gave the company a “market outperform” rating in a research report on Wednesday, November 5th. Finally, Needham & Company LLC restated a “buy” rating and set a $10.00 price target on shares of Taysha Gene Therapies in a research note on Friday, October 17th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Taysha Gene Therapies currently has a consensus rating of “Moderate Buy” and an average target price of $10.67.

Key Taysha Gene Therapies News

Here are the key news stories impacting Taysha Gene Therapies this week:

• Positive Sentiment: Analyst outlook remains constructive: several firms have raised price targets and reiterated buy/outperform ratings (Wells Fargo, Robert W. Baird, Needham, JMP, Citizens/JMP). This supports upside vs. current levels.
• Positive Sentiment: Notable institutional activity: multiple funds reported adding or building positions (MarketBeat summary highlights large additions), which can be a longer?term vote of confidence.
• Neutral Sentiment: Recent earnings matched estimates (Q3 EPS -$0.09), and consensus expects continued losses this year — typical for a clinical?stage biotech; no near?term revenue catalysts were reported. Earnings & Consensus
• Neutral Sentiment: Technical/market context: shares had elevated volume vs. average and sit between the 50?day (~$5.09) and 200?day (~$4.08) moving averages; valuation remains typical for pre?revenue gene therapy names (negative P/E). Quote & Technicals
• Negative Sentiment: Insider selling — CFO Kamran Alam: sold 78,968 shares (Jan. 23) and 23,849 shares (Jan. 26), reducing his stake; the Jan. 26 sale filed with the SEC. CFO Form 4
• Negative Sentiment: Insider selling — CEO Sean P. Nolan: sold 136,789 shares (Jan. 23) and 41,312 shares (Jan. 26), reducing his ownership; filings are public with the SEC. CEO Form 4
• Negative Sentiment: Insider selling — director Sukumar Nagendran: sold 89,132 shares (Jan. 23) and 26,918 shares (Jan. 26), further insider reductions reported. Director Form 4

Institutional Trading of Taysha Gene Therapies

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Marex Group plc purchased a new position in shares of Taysha Gene Therapies in the 2nd quarter valued at approximately $29,000. E Fund Management Co. Ltd. acquired a new stake in shares of Taysha Gene Therapies during the second quarter worth $31,000. ST Germain D J Co. Inc. grew its position in Taysha Gene Therapies by 81.8% in the 3rd quarter. ST Germain D J Co. Inc. now owns 9,633 shares of the company’s stock valued at $32,000 after buying an additional 4,333 shares during the last quarter. May Hill Capital LLC purchased a new position in Taysha Gene Therapies in the 2nd quarter valued at $37,000. Finally, Arrowpoint Investment Partners Singapore Pte. Ltd. acquired a new position in Taysha Gene Therapies in the 3rd quarter valued at $40,000. 77.70% of the stock is owned by hedge funds and other institutional investors.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.